| abstract |
FIELD: chemistry. n SUBSTANCE: invention refers to new phenyl derivatives with the formula (I) where # symbol indicates two carbon atoms of the phenyl ring bearing R 1 , R 2 and R 3 ; to each of the latter components the A group can be linked; and where A represents or where asterisks indicate the link through which the formula (I) is linked to the phenyl ring bearing R 1 , R 2 and R 3 ; R 1 represents hyndrogen or C 1-3 -alkyl; R 2 represents C 2-5 -alkyl or C 1-4 -alkoxy group; R 3 represents hydrogen, and in case when the A group is linked in the para-position in relation to the phenyl ring of the formula (I) bearing R 1 , R 2 and R 3 , R 3 can additionally represent the methyl group; R 4 represents hydrogen; R 5 represents C 1-3 -alkyl; R 6 represents a hydroxy group, di-(hydroxy-C 1-4 -alkyl)-C 1-4 -alkoxy group, 2,3-dihydroxypropoxy group, -OCH 2 -CH(OH)-CH 2 -NR 61 R 62 or -OCH 2 -CH(OH)-CH 2 -NHCOR 64 ; R 61 represents hydrogen; R 62 represents hydrogen; R 64 represents hydroxymethyl; and R 7 represents C 1-3 -alkyl; and to its salt. The invention also refers to the pharmaceutical composition that is agonistic in relation to S1P1/EDG1 receptor on the basis of the mentioned compounds. n EFFECT: new compounds and the pharmaceutical composition based on them that may find their application in medicine as immunomodulating agents. n 18 cl, 2 tbl, 28 ex |